İbrahim KARNAK, Feridun Cahit TANYEL, Tutku SOYER, Sinan KILIÇ, Mehmet Emin ŞENOCAK, Arbay Özden ÇİFTÇİ

Evaluation of the removal reasons of totally implantable venous devices in children: a retrospective study

SUMMARY: Kılıç S, Soyer T, Karnak İ, Çiftçi AÖ, Tanyel FC, Şenocak ME. Evaluation of the removal reasons of totally implantable venous devices in children: a retrospective study. Turk J Pediatr 2016; 58: 187-194. Totally implantable venous access devices (TIVADs) increase the quality of life in children with hematologic and oncologic diseases or organ failures. The aim of this study is to determine the reasons for port removal. The port catheters, implanted and removed in patients between January 2000 and June 2013 were evaluated retrospectively. The patients were divided into two groups, whose port catheters were removed due to completed therapy (completed therapy group, CTG) and whose port catheters were removed because of a port catheter-related complications (complication group, CG). In the CG, the patients whose port catheters are removed for infectious reasons are investigated for whether there is a relationship with age, gender, body mass index (BMI), height and weight at the time of port implantation and removal. In total, 242 patients who underwent port implantation and removal were included in the study. The male to female ratio was 1.32/1 and the mean age of the patients was 9.4±4.9 years (0-24 year). Patients were enrolled in CTG (n=170, 70.2%), and CG (n=72, 29%). There is a positive correlation between BMI and infections (p

PDF

___

1. Funaki B. Central venous access: a primer for the diagnostic radiologist. AJR Am J Roentgenol 2002; 179: 309-318.
2. Biffi R, Toro A, Pozzi S, Di Carlo I. Totally implantable vascular access devices 30 years after the first procedure. What has changed and what is still unsolved? Support Care Cancer 2014; 22: 1705-1714.
3. Coppa GF, Gouge TH, Hofstetter SR. Air embolism: a lethal but preventable complication of subclavian vein catheterization. JPEN J Parenter Enteral Nutr 1981; 5: 166-168.
4. Ezaru CS, Mangione MP, Oravitz TM, Ibinson JW, Bjerke RJ. Eliminating arterial injury during central venous catheterization using manometry. Anesth Analg 2009; 109: 130-134.
5. Faraj W, Zaghal A, El-Beyrouthy O, Kutoubi A. Complete catheter disconnection and migration of an implantable venous access device: the disconnected cap sign. Ann Vasc Surg 2010; 24: 692.e11-e15.
6. Burns S, Herbison GJ. Spinal accessory nerve injury as a complication of internal jugular vein cannulation. Ann Intern Med 1996; 125: 700.
7. Wiegand UK, LeJeune D, Boguschewski F, et al. Pocket hematoma after pacemaker or implantable cardioverter defibrillator surgery: influence of patient morbidity, operation strategy, and perioperative antiplatelet/ anticoagulation therapy. Chest 2004; 126: 1177-1186.
8. Zawacki WJ, Walker TG, DeVasher E, et al. Wound dehiscence or failure to heal following venous access port placement in patients receiving bevacizumab therapy. J Vasc Interv Radiol 2009; 20: 624-627.
9. Flynn PM, Shenep JL, Stokes DC, Barrett FF. In situ management of confirmed central venous catheterrelated bacteremia. Pediatr Infect Dis J 1987; 6: 729- 734.
10. de Jonge RC, Polderman KH, Gemke RJ. Central venous catheter use in the pediatric patient: mechanical and infectious complications. Pediatr Crit Care Med 2005; 6: 329-339.
11. Lokich JJ, Bothe A Jr, Benotti P, Moore C. Complications and management of implanted venous access catheters. J Clin Oncol 1985; 3: 710-717.
12. Kurul S, Saip P, Aydin T. Totally implantable venousaccess ports: local problems and extravasation injury. Lancet Oncol 2002; 3: 684-692.
13. Biffi R, de Braud F, Orsi F, et al. Totally implantable central venous access ports for long-term chemotherapy. A prospective study analyzing complications and costs of 333 devices with a minimum follow-up of 180 days. Ann Oncol 1998; 9: 767-773.
14. Jueckstock JK, Mylonas I, Strobl B, Willgeroth F, Sommer HL, Friese K. Paravasation with cyclophosphamide – case report of tissue necrosis in a patient with primary breast cancer. Onkologie 2007; 30: 452-454.
15. O’Grady NP, Alexander M, Burns LA, et al. Guidelines for the prevention of intravascular catheter-related infections. Am J Infect Control 2011; 39: (4 Suppl 1) S1-S34.
16. Mangram AJ, Horan TC, Pearson ML, Silver LC, Jarvis WR, Guideline for prevention of surgical site infection. 1999 Hospital Infection Control Practices Advisory Committee. Infect Control Hosp Epidemiol 1999; 20: 250-278.
17. Filippou DK, Tsikkinis C, Filippou GK, Nissiotis A, Rizos S. Rupture of totally implantable central venous access devices (Intraports) in patients with cancer: report of four cases. World J Surg Oncol 2004; 2: 36.
18. Jost K, Leithauser M, Grosse-Thie C, et al. Perforation of the superior vena cava - a rare complication of central venous catheters. Onkologie 2008; 31: 262-264.
19. McMahon C, Smith J, Khair K, Liesner R, Hann IM. Smith OP. Central venous access devices in children with congenital coagulation disorders: complications and long-term outcome. Br J Haematol 2000; 110: 461-468.
20. Yazıcı N, Akyüz C, Yalçın B, Varan A, Kutluk T, Büyükpamukçu M. Infectious complications and conservative treatment of totally implantable venous access devices in children with cancer Turk J Pediatr 2013; 55: 164-171.
21. Ingram J, Weitzman S, Greenberg ML, Parkin P, Filler R. Complications of indwelling venous access lines in the pediatric hematology patient: a prospective comparison of external venous catheters and subcutaneous ports. Am J Pediatr Hematol Oncol 1991; 13: 130-136.
22. Hollyoak MA, Ong TH, Leditschke JF. Critical appraisal of surgical venous access in children. Pediatr Surg Int 1997; 12: 177-182.
23. Trerotola SO, Kuhn-Fulton J, Johnson MS, Shah H, Ambrosius WT, Kneebone PH. Tunneled infusion catheters: increased incidence of symptomatic venous thrombosis after subclavian versus internal jugular venous access. Radiology 2000; 217: 89-93.
24. Özbudak E, Yavuz Ş, Akgül A ve ark. Kalıcı hemodiyaliz kateterleri: Ne kadar kalıcı? Türk Göğüs Kalp Damar Cerrahisi Dergisi 2013; 21: 646-653.
25. Chauhan A, Lebeaux D, Ghigo JM, Beloin C. Full and broad-spectrum in vivo eradication of catheterassociated biofilms using gentamicin-EDTA antibiotic lock therapy. Antimicrob Agents Chemother 2012; 56: 6310-6138.
26. National Nosocomial Infections Surveillance (NNIS) System Report, Data Summary from January 1990- May 1999, Issued June 1999. A report from the NNIS System. Am J Infect Control 1999; 27: 520-532.
27. Schaberg DR, Culver DH, Gaynes RP. Major trends in the microbial etiology of nosocomial infection. Am J Med 1991; 91: 72S-75S.
28. Abbas AA, Fryer CJ, Paltiel C, et al. Factors influencing central line infections in children with acute lymphoblastic leukemia results of a single institutional study. Pediatr Blood Cancer 2004; 42: 325-331.